Reva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device.
The Fantom Encore product is a third-gen coronary bioresorbable scaffold featuring a thin strut profile and Reva’s Tyrocore polymer.
Get the full story at our sister site, Drug Delivery Business News.
The post Reva launches Fantom Encore bioresorbable scaffold appeared first on MassDevice.